The Clorox Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLX research report →
Range $83 – $127
Price Chart
About the company
The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness division offers a range of cleaning solutions, including laundry additives and home care items under brand names such as Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409. It also supplies professional cleaning and disinfecting products via the CloroxPro and Clorox Healthcare brands, alongside professional food service goods from Hidden Valley.
- CEO
- Linda J. Rendle
- IPO
- 1983
- Employees
- 7,600
- HQ
- Oakland, CA, US
AI snapshot
Six angles, distilled from the data.
CLX is in a recovery regime after a deep drawdown, trading back above its 200-day moving average and well off the 52-week low of 84.7. The setup is constructive but still mid-range, with the stock below its 52-week high of 127.2954 and not yet back in a full momentum breakout.
Street sentiment is cautious: the consensus is Hold with 20 Holds, 3 Buys, and 6 Sells. The average target sits at 101.8, below the current share price, while recent calls were mixed with several target raises offset by Jefferies’ downgrade and Barclays’ lower target.
The earnings profile is solid but not flawless, with 6 beats in the last 8 quarters and a fresh beat on 2026-08-03. Next-year EPS is modeled higher at 5.9543 versus TTM EPS of 4.79, so shareholders should watch whether margin discipline can keep the beat streak intact.
No discretionary insider buying or selling stands out. Recent activity is dominated by automatic award and in-kind entries for directors and executives, which reads as routine compensation rather than a directional signal.
Profitability remains respectable, led by a 42.8% gross margin and 16.38% operating margin. Growth is softer, with revenue down 2.0% year over year and earnings down 50.1%, while free cash flow of $1.201 billion and a 9.41% FCF yield support the balance sheet despite $5.52 billion of debt and only $143 million of cash.
CLX’s defensive brand portfolio and household staples exposure support steadier margins than many consumer names, but growth is slower and leverage is heavier than ideal. At 19.04x earnings, the valuation is not cheap for a low-beta staple with muted top-line momentum.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.65B
- P/E
- 21.72
- Fwd P/E
- 17.89
- PEG
- -0.81
- P/S
- 1.88
- P/B
- 141.62
- EV/EBITDA
- 19.58
- Div Yield
- 4.75%
- Gross Margin
- 42.32%
- Op Margin
- 24.73%
- Net Margin
- 8.74%
- ROE
- -1893.55%
- ROIC
- 20.39%
Latest fiscal year · YoY change
- Revenue
- $6.72B-5.4%
- Gross Profit
- $2.84B-11.5%
- Op Income
- $1.66B
- Net Income
- $587.00M-27.5%
- EPS
- $4.82-26.5%
- OCF Growth
- -37.6%
- FCF Growth
- -46.8%
- 52W High
- $128.90
- 52W Low
- $84.70
- 50D MA
- $97.20
- 200D MA
- $103.70
- Beta
- 0.53
- RSI (14)
- 58
- Avg Volume
- 2.87M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Clorox said fiscal 2026 ended with sequential improvement and strong share gains in several businesses, while fiscal 2027 will still face elevated inflation and a muted category backdrop.· August 3, 2026
- Fiscal 2026 saw sequential improvement in consumption, share, and distribution, with June exit rates near flat and many businesses performing at or above expectations.
- Management expects fiscal 2027 organic sales to be flat to slightly up, with Q1 softer due to Kingsford timing and promotional noise before improvement later in the year.
- Inflation is expected to be above $200 million in fiscal 2027, driven by commodities plus logistics and supply-chain costs, with Brent assumed at about $90 per barrel.
- GOJO/Purell is already performing ahead of plan, was accretive in Q4, and is expected to be accretive to adjusted EPS next year.
- Clorox is leaning on targeted pricing, productivity, and brand reinvestment rather than broad-based price hikes; Glad is the main category called out for a more direct price increase.
Clorox did not state full-quarter revenue, EPS, or gross margin results in the prepared remarks and Q&A shown here. For fiscal 2027, management guided to organic sales that are flat to slightly up, reiterated a gross margin target around 42%, and said inflation should be above $200 million, more than double the historical $75 million to $100 million range. Luc Bellet also said free cash flow should remain in the company’s targeted 11% to 13% of sales range, SG&A should improve on a comparable basis, and interest expense is about $210 million. On the GOJO acquisition, Bellet said the business was accretive in Q4, expected to be accretive to adjusted EPS next fiscal year, and should run at mid-single-digit growth with potential to move to mid- to high-single digits as synergies build.
Linda Rendle framed fiscal 2026 as a year of urgent execution in a difficult environment marked by value-seeking consumers, competition, inflation, and macro uncertainty. Her tone was constructive and disciplined: she emphasized superiority, targeted reinvestment, and a stronger foundation for fiscal 2027, while saying the company is making sequential progress even if some businesses still need work. She also stressed that Clorox will continue to review the portfolio carefully, but there is nothing to announce yet.
Luc Bellet focused on inflation, margins, cash flow, and capital structure. He said fiscal 2027 inflation is expected to be above $200 million, with Brent crude assumed at about $90 per barrel and additional pressure from supplier costs, ocean freight, trucking, and logistics; he also noted the impact should be more pronounced in the first half. He said free cash flow should stay in the 11% to 13% of sales range, helped by working capital discipline, GOJO’s stable cash generation, and expected tax benefits. On SG&A, he said comparable productivity should exceed inflation next year, and on interest expense he said it is about $210 million.
Analysts pressed on the flat-to-slightly-up sales outlook, asking how much of the improvement comes from share gains versus easing timing issues. Management said Q1 is mainly a timing blip from Kingsford and some promotional shifts, and that the back half of the year should look more like fiscal 2026 trends, with share improvement continuing. Questions also focused on pricing, promotions, and whether the company has pricing power; management said pricing will be targeted rather than broad, with Glad getting a straight price increase and other categories using price pack architecture, promotions, and product improvements. Analysts also asked about GOJO, portfolio trimming, dividend policy, ERP savings, and the CEO search; management said GOJO is ahead of plan, the dividend remains supported, ERP benefits should ramp later this year and next, and the CEO search is progressing as expected.
The bull case from this call is that Clorox believes it has already moved past the worst operational issues and is seeing sequential share recovery in multiple businesses. Management pointed to Home Care’s eight straight quarters of share growth, strong Pro and International performance, a turnaround in Glad and Hidden Valley, and early progress in Litter and Fresh Step. They also said GOJO is performing ahead of plan and should add growth and cash flow, while ERP and Global Business Services should support efficiency gains later in fiscal 2027 and beyond.
The main risks are a still-muted consumer and category backdrop, above-normal inflation, and a soft Q1 due to timing issues in Kingsford and promotion. Management acknowledged that Litter remains a work in progress, Kingsford was hurt by weather and retailer merchandising choices, and fiscal 2027 gross margin recovery will be incomplete because inflation is concentrated in the first half. The company also said promotions remain elevated and that pricing must be carefully balanced so it does not damage share gains.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 120.92M
- Float Shares
- 120.01M
of shares held by institutions
1,123 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CLX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | May 15, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 19, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
| Lisa McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Apr 11, 25 | Filing → |
| Tommy TubervilleSenate · AL | Buy | Apr 29, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 20, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 3, 23 | Filing → |
| Tommy TubervilleSenate · AL | Sell | Oct 31, 23 | Filing → |
| Tommy TubervilleSenate · AL | Buy | Oct 25, 23 | Filing → |
| Tommy TubervilleSenate · AL | Sell | Oct 31, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 15.68M | ▼ 54.68K |
| Blackrock, Inc. | 10.04M | ▼ 127.45K |
| State Street Corp | 8.43M | ▲ 177.95K |
| Vanguard Capital Management LLC | 7.85M | ▲ 7.85M |
| Invesco Ltd. | 4.86M | ▼ 21.10K |
| Geode Capital Management, LLC | 3.27M | ▲ 36.87K |
| Van Eck Associates Corp | 3.22M | ▲ 81.97K |
| Morgan Stanley | 2.72M | ▲ 422.89K |
| Proshare Advisors LLC | 1.64M | ▲ 119.25K |
| Point72 Asset Management, L.P. | 1.59M | ▲ 1.23M |
| Northern Trust Corp | 1.59M | ▲ 16.95K |
| Fmr LLC | 1.47M | ▲ 822.02K |
Held by 1,197 ETFs
Biggest fund positions in CLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Barton Nina | other | 1,681 |
| Jul 15, 26 | Hyder Chris T | other | 277 |
| Jun 30, 26 | WILLIAMS CHRISTOPHER J | other | 288.139 |
| May 8, 26 | WILLIAMS CHRISTOPHER J | other | 297.01 |
| Jun 30, 26 | WEINER RUSSELL J | other | 353.625 |
| May 8, 26 | WEINER RUSSELL J | other | 242.241 |
| Jun 30, 26 | Plaines Stephanie | other | 288.139 |
| May 8, 26 | Plaines Stephanie | other | 103.94 |
| Jun 30, 26 | Shattock Matthew J | other | 550.084 |
| May 8, 26 | Shattock Matthew J | other | 270.796 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLX coverage
Recent articles, reports, and earnings notes.

Clorox (CLX): Execution Risk vs. Brand Strength
Clorox remains a durable branded-staples name, but flat revenue, higher debt, and a difficult ERP transition keep the stock in Hold territory. Household and International are improving, yet Fresh Step and Food remain key execution challenges.

Clorox (CLX): ERP Reset Masks a Fairly Priced Recovery
Clorox rebuilt profitability in fiscal 2025, but FY2026 guidance was cut sharply as ERP-related inventory drawdown hit sales and margins. The stock looks like a steady staples franchise in repair, with valuation close to fair and upside tied to execution.

The Clorox Company (CLX) drops 9% on profit outlook cut
The Clorox Company (CLX) drops sharply after cutting full-year profit guidance and warning that gross margins will weaken more than expected. The consumer staples name posted a mixed quarter, but investors are focusing on lower earnings power, margin pressure, and a tougher near-term outlook.
Want a deeper read on CLX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
NWL vs. CLX: Which Stock Is the Better Value Option?
zacks.com · Aug 6
Clorox Q4 Earnings & Sales Top Estimates as GOJO Supports Sales
zacks.com · Aug 4
CLX Q4 Earnings Call Flags Inflation as Share Recovery Builds
zacks.com · Aug 4
These Analysts Boost Their Forecasts On Clorox Following Better-Than-Expected Q4 Results
benzinga.com · Aug 4
Clorox: Follow Consumers Trends By Seeking Value Elsewhere (Rating Downgrade)
seekingalpha.com · Aug 4
The Clorox Company (CLX) Q4 2026 Earnings Call Transcript
seekingalpha.com · Aug 3
Clorox (CLX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com · Aug 3
Clorox Q4 Earnings Call Highlights
marketbeat.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed August 7, 2026 · Live quote · Not investment advice